US Regulator's Rejection of Psychedelic MDMA as Treatment for PTSD Sends Shockwaves Through Market

Tuesday, 4 June 2024, 22:49
The recent decision by the FDA panel to reject the use of psychedelic MDMA as a treatment for PTSD is a setback for both drug developers and investors. While the vote is non-binding, it carries significant influence with the agency, signaling challenges for the fledgling industry. This development has raised uncertainties and impacted the outlook for companies in the psychedelic drug space.
LivaRava Finance Meta Image
US Regulator's Rejection of Psychedelic MDMA as Treatment for PTSD Sends Shockwaves Through Market

US regulator rejects psychedelic MDMA as treatment for PTSD

FDA panel’s vote is non-binding but carries influence with agency in blow to fledgling drug developers and investors

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.

Related posts

Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe